Jump to main content
Jump to site search


Investigation and Bioorthogonal Anticancer Activity Enhancement of Triphenylphosphine-labile Prodrug of Seleno-Combretastatin-4

Abstract

Here, the triphenylphosphine (TPP)-labile prodrug of seleno-Combretastatin-4 (CSeD) has been designed and synthesized. A detail investigation was revealed that CSeD which showed higher safety in the blood circulation could react with TPP to release CA-4 and selenodiazole derivative, accompanying powerful anticancer, antiangiogenesis effects and radiosentization property.

Back to tab navigation

Supplementary files

Article information


Submitted
12 Aug 2020
Accepted
15 Oct 2020
First published
15 Oct 2020

Chem. Commun., 2020, Accepted Manuscript
Article type
Communication

Investigation and Bioorthogonal Anticancer Activity Enhancement of Triphenylphosphine-labile Prodrug of Seleno-Combretastatin-4

P. Feng, L. Hou, W. Huang, J. Cheng, X. Deng, H. Lai, Z. Chen, Z. Zhan, Y. Li, F. Yang and T. Chen, Chem. Commun., 2020, Accepted Manuscript , DOI: 10.1039/D0CC05498D

Social activity

Search articles by author

Spotlight

Advertisements